Flare Platform Program

About Dispatch Bio

Dispatch Bio is a private, preclinical-stage biotech developing a universal treatment for solid tumors using its first-in-class Flare platform. The platform combines a tumor-specific virus with a novel universal antigen to precisely tag and clear cancer cells while overcoming the immunosuppressive tumor microenvironment. Backed by a seasoned leadership team with deep drug development experience and notable investors like ARCH Venture Partners, the company aims to address the significant unmet need in oncology, where solid tumors represent approximately 90% of all cancers.

Therapeutic Areas

Other Solid Tumors Drugs